Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 7:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Autoimmune Connective Tissue Disorder Clear all
Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

NCT01377012
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Secukinumab (AIN457), Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
39
States / cities
Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 24, 2026, 7:38 AM EDT
Completed Not applicable Interventional Results available

Persona TM Tibia Clinical Outcomes Study

NCT03589300
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Collagen Disorders and/or Avascular Necrosis of the Femoral Condyle, Post-traumatic Loss of Joint Configuration, Moderate Valgus, Varus, or Flexion Deformities
Interventions
Persona TM Tibia
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Torrance, California • Wheat Ridge, Colorado • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 24, 2026, 7:38 AM EDT
Recruiting No phase listed Observational

Early Rheumatoid Arthritis Lung Disease Study

NCT03192267
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 90 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 24, 2026, 7:38 AM EDT
Active, not recruiting Not applicable Interventional

A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis.

NCT06513507
View directory record Official record
Conditions
Rheumatoid Arthritis, Inflammatory Disease
Interventions
Cannabigerol (CBG)
Dietary Supplement
Lead sponsor
Raphael Pharma
Industry
Eligibility
25 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 24, 2026, 7:38 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Whole Body Hyperthermia Registry Study

NCT02174003
View directory record Official record
Conditions
Depression, Anxiety, PTSD, Fibromyalgia, Chronic Fatigue Syndrome
Interventions
High intensity whole-body infrared heating
Device
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 24, 2026, 7:38 AM EDT
Completed Phase 3 Interventional

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

NCT04930094
View directory record Official record
Conditions
Giant Cell Arteritis (GCA)
Interventions
Secukinumab 300 mg, Placebo, Secukinumab 150 mg
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 100 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Plantation, Florida • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 24, 2026, 7:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of Duloxetine in the Reduction of Pain in Patient With Systemic Lupus Erythematosus

NCT01269866
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Cymbalta
Drug
Lead sponsor
Dr. Jesus Gutierrez Stone
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 24, 2026, 7:38 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis

NCT01369745
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Prednisolone, dipyridamole, Prednisone, Z102, placebo
Drug · Other
Lead sponsor
Zalicus
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Sep 24, 2026, 7:38 AM EDT
Completed Phase 2 Interventional Results available

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

NCT01649765
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab 10 mg/kg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 17 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 24, 2026, 7:38 AM EDT
Terminated Phase 3 Interventional Results available

A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)

NCT01292265
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Walnut Creek, California • Wheaton, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 24, 2026, 7:38 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT04294667
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DZP, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
16 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 24, 2026, 7:38 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of M2951 in SLE

NCT02975336
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, M2951
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
42
States / cities
Anniston, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 24, 2026, 7:38 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003

NCT01856309
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Sirukumab 100 mg, Sirukumab 50 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
66
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated May 5, 2019 · Synced Sep 24, 2026, 7:38 AM EDT
Completed Phase 2 Interventional

Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis

NCT00141830
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate plus ERB-041 for 12 weeks, Placebo for 12 weeks
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
14
States / cities
Largo, Florida • Palm Harbor, Florida • Sarasota, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Sep 24, 2026, 7:38 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis

NCT00626275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ADL5859, Naproxen, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Trumbull, Connecticut • Daytona Beach, Florida • Wheaton, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 24, 2026, 7:38 AM EDT
Terminated Phase 4 Interventional Results available

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor

NCT01283971
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], adalimumab, placebo to tocilizumab, placebo to adalimumab, methotrexate, folate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
107
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Sep 24, 2026, 7:38 AM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris

NCT01930175
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
VAY736, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
20 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Sep 24, 2026, 7:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lupus Genetics Studies

NCT00071175
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
Not listed
Enrollment
3,460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 24, 2026, 7:38 AM EDT
Completed Phase 3 Interventional Results available

A Study in Moderate to Severe Rheumatoid Arthritis Participants

NCT01721057
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Baricitinib, cDMARD
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
48
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 24, 2026, 7:38 AM EDT
Not yet recruiting Not applicable Interventional

Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress

NCT06999109
View directory record Official record
Conditions
Lupus, Dermatomyositis, Juvenile, Dermatomyositis, Lupus Erythematosus, Lupus Erythematosus, Systemic, Lupus or SLE
Interventions
TEAM-LEADS
Behavioral
Lead sponsor
Duke University
Other
Eligibility
13 Years to 22 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 24, 2026, 7:38 AM EDT
Completed Phase 2 Interventional

DHEA Treatment for Sjogren's Syndrome

NCT00001598
View directory record Official record
Conditions
Lacrimal Apparatus Disease, Salivary Gland Disease, Sjogren's Syndrome, Xerostomia
Interventions
Dehydroepiandrosterone
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 24, 2026, 7:38 AM EDT
Terminated Phase 1 Interventional Results available

Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism

NCT00282412
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Hematopoietic Stem Cell Transplantation, Fludarabine, Cyclophosphamide, Campath 1H, GCSF, Cyclosporins, Mycophenolate Mofetil
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 24, 2026, 7:38 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies

NCT00805467
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib Disodium (R935788)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
35
States / cities
La Jolla, California • Palm Desert, California • Palo Alto, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Sep 24, 2026, 7:38 AM EDT
Not listed Phase 3 Interventional

The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis

NCT00012506
View directory record Official record
Conditions
Uveitis, Arthritis, Juvenile Rheumatoid
Interventions
TNFR:Fc
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 24, 2026, 7:38 AM EDT